Literature DB >> 23069638

Mapping domains and mutations on the skeletal muscle ryanodine receptor channel.

Jean H Hwang1, Francesco Zorzato, Nigel F Clarke, Susan Treves.   

Abstract

The skeletal muscle ryanodine receptor isoform 1 (RyR1) is a calcium release channel involved in excitation-contraction coupling, the process whereby an action potential is translated to a cytoplasmic Ca(2+) signal that activates muscle contraction. Dominant and recessive mutations in RYR1 cause a range of muscle disorders, including malignant hyperthermia and several forms of congenital myopathies. Many aspects of disease pathogenesis in ryanodinopathies remain uncertain, particularly for those myopathies due to recessive mutations. A thorough understanding of the ryanodine receptor macromolecular complex and its interactions with proteins and small molecular modulators is an essential starting point from which to investigate disease mechanisms.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23069638     DOI: 10.1016/j.molmed.2012.09.006

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  25 in total

Review 1.  Ca2+ Release Channels Join the 'Resolution Revolution'.

Authors:  Ran Zalk; Andrew R Marks
Journal:  Trends Biochem Sci       Date:  2017-05-09       Impact factor: 13.807

2.  Characterization and genetic diagnosis of centronuclear myopathies in seven Chinese patients.

Authors:  Yan Zhao; Zhe Zhao; Hongrui Shen; Qi Bing; Jing Hu
Journal:  Neurol Sci       Date:  2018-09-19       Impact factor: 3.307

3.  Regulation of the skeletal muscle ryanodine receptor/Ca2+-release channel RyR1 by S-palmitoylation.

Authors:  Ruchi Chaube; Douglas T Hess; Ya-Juan Wang; Bradley Plummer; Qi-An Sun; Kennneth Laurita; Jonathan S Stamler
Journal:  J Biol Chem       Date:  2014-02-07       Impact factor: 5.157

Review 4.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR1 or CACNA1S Genotypes.

Authors:  Stephen G Gonsalves; Robert T Dirksen; Katrin Sangkuhl; Rebecca Pulk; Maria Alvarellos; Teresa Vo; Keiko Hikino; Dan Roden; Teri E Klein; S Mark Poler; Sephalie Patel; Kelly E Caudle; Ronald Gordon; Barbara Brandom; Leslie G Biesecker
Journal:  Clin Pharmacol Ther       Date:  2019-01-24       Impact factor: 6.875

Review 5.  Ryanodine Receptor Structure and Function in Health and Disease.

Authors:  Gaetano Santulli; Daniel Lewis; Amedee des Georges; Andrew R Marks; Joachim Frank
Journal:  Subcell Biochem       Date:  2018

6.  Oxygen-coupled redox regulation of the skeletal muscle ryanodine receptor/Ca2+ release channel (RyR1): sites and nature of oxidative modification.

Authors:  Qi-An Sun; Benlian Wang; Masaru Miyagi; Douglas T Hess; Jonathan S Stamler
Journal:  J Biol Chem       Date:  2013-06-24       Impact factor: 5.157

Review 7.  Physiology and pathophysiology of excitation-contraction coupling: the functional role of ryanodine receptor.

Authors:  Gaetano Santulli; Daniel R Lewis; Andrew R Marks
Journal:  J Muscle Res Cell Motil       Date:  2017-06-26       Impact factor: 2.698

8.  Malignant hyperthermia-associated mutations in the S2-S3 cytoplasmic loop of type 1 ryanodine receptor calcium channel impair calcium-dependent inactivation.

Authors:  Angela C Gomez; Timothy W Holford; Naohiro Yamaguchi
Journal:  Am J Physiol Cell Physiol       Date:  2016-08-24       Impact factor: 4.249

Review 9.  PharmGKB summary: very important pharmacogene information for RYR1.

Authors:  Maria L Alvarellos; Ronald M Krauss; Russell A Wilke; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2016-03       Impact factor: 2.089

Review 10.  Congenital myopathies: disorders of excitation-contraction coupling and muscle contraction.

Authors:  Heinz Jungbluth; Susan Treves; Francesco Zorzato; Anna Sarkozy; Julien Ochala; Caroline Sewry; Rahul Phadke; Mathias Gautel; Francesco Muntoni
Journal:  Nat Rev Neurol       Date:  2018-02-02       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.